124 related articles for article (PubMed ID: 34309735)
21. Can adaptive threshold-based metabolic tumor volume (MTV) and lean body mass corrected standard uptake value (SUL) predict prognosis in head and neck cancer patients treated with definitive radiotherapy/chemoradiotherapy?
Akagunduz OO; Savas R; Yalman D; Kocacelebi K; Esassolak M
Nucl Med Biol; 2015 Nov; 42(11):899-904. PubMed ID: 26275933
[TBL] [Abstract][Full Text] [Related]
22. Institutional clinical trial accrual volume and survival of patients with head and neck cancer.
Wuthrick EJ; Zhang Q; Machtay M; Rosenthal DI; Nguyen-Tan PF; Fortin A; Silverman CL; Raben A; Kim HE; Horwitz EM; Read NE; Harris J; Wu Q; Le QT; Gillison ML
J Clin Oncol; 2015 Jan; 33(2):156-64. PubMed ID: 25488965
[TBL] [Abstract][Full Text] [Related]
23. Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
Yi J; Huang X; Xu Z; Liu S; Wang X; He X; Luo D; Luo J; Xiao J; Zhang S; Wang K; Qu Y; Tang Y; Liu W; Xu G; Gao L; Wang D
Oncotarget; 2017 Jul; 8(27):44842-44850. PubMed ID: 28179586
[TBL] [Abstract][Full Text] [Related]
24. c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation.
Baschnagel AM; Williams L; Hanna A; Chen PY; Krauss DJ; Pruetz BL; Akervall J; Wilson GD
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):701-7. PubMed ID: 24521684
[TBL] [Abstract][Full Text] [Related]
25. XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation.
Lopes-Aguiar L; Costa EF; Nogueira GA; Lima TR; Visacri MB; Pincinato EC; Calonga L; Mariano FV; de Almeida Milani Altemani AM; Altemani JM; Coutinho-Camillo CM; Ribeiro Alves MA; Moriel P; Ramos CD; Chone CT; Lima CS
Oncotarget; 2017 Mar; 8(10):16190-16201. PubMed ID: 26918827
[TBL] [Abstract][Full Text] [Related]
26. Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience.
Ock CY; Keam B; Lim Y; Kim TM; Lee SH; Kwon SK; Hah JH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
Head Neck; 2016 Feb; 38(2):277-84. PubMed ID: 26104823
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
Hitt R; Iglesias L; López-Pousa A; Berrocal-Jaime A; Grau JJ; García-Girón C; Martínez-Trufero J; Guix M; Lambea-Sorrosal J; Del Barco-Morillo E; León-Vintró X; Cunquero-Tomas AJ; Baste N; Ocaña A; Cruz-Hernández JJ;
Clin Transl Oncol; 2021 Apr; 23(4):764-772. PubMed ID: 32797376
[TBL] [Abstract][Full Text] [Related]
28. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Yang Y; Xian L
Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
[TBL] [Abstract][Full Text] [Related]
29. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
Choe KS; Haraf DJ; Solanki A; Cohen EE; Seiwert TY; Stenson KM; Blair EA; Portugal L; Villaflor VM; Witt ME; Vokes EE; Salama JK
Cancer; 2011 Oct; 117(20):4671-8. PubMed ID: 21671479
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
[TBL] [Abstract][Full Text] [Related]
31. Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base.
Amini A; Jones BL; McDermott JD; Serracino HS; Jimeno A; Raben D; Ghosh D; Bowles DW; Karam SD
Cancer; 2016 May; 122(10):1533-43. PubMed ID: 26969811
[TBL] [Abstract][Full Text] [Related]
32. Is definitive concurrent chemoradiotherapy effective for locally advanced head and neck cancer in the elderly aged ≥ 75 years: A single-institute, retrospective, cohort study.
Lai KM; Lin JT; Lu HJ; Liang CC; Chen MK
Asia Pac J Clin Oncol; 2018 Jun; 14(3):247-255. PubMed ID: 28840980
[TBL] [Abstract][Full Text] [Related]
33. Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".
Schüttrumpf L; Marschner S; Scheu K; Hess J; Rietzler S; Walch A; Baumeister P; Kirchner T; Ganswindt U; Zitzelsberger H; Belka C; Maihoefer C
Radiat Oncol; 2020 Jan; 15(1):7. PubMed ID: 31906998
[TBL] [Abstract][Full Text] [Related]
34. Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers : Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94).
Ghadjar P; Pöttgen C; Joos D; Hayoz S; Baumann M; Bodis S; Budach W; Studer G; Stromberger C; Zimmermann F; Kaul D; Plasswilm L; Olze H; Bernier J; Wust P; Aebersold DM; Budach V
Strahlenther Onkol; 2016 Aug; 192(8):552-60. PubMed ID: 27323753
[TBL] [Abstract][Full Text] [Related]
35. DNA repair gene ERCC2 polymorphisms and risk of squamous cell carcinoma of the head and neck.
Gugatschka M; Dehchamani D; Wascher TC; Friedrich G; Renner W
Exp Mol Pathol; 2011 Aug; 91(1):331-4. PubMed ID: 21419115
[TBL] [Abstract][Full Text] [Related]
36. Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥70years.
Strom TJ; Naghavi AO; Trotti AM; Russell J; Kish JA; McCaffrey J; Otto KJ; Harrison LB; Caudell JJ
J Geriatr Oncol; 2017 Jan; 8(1):50-55. PubMed ID: 27720129
[TBL] [Abstract][Full Text] [Related]
37. Prognostic and predictive significance of nuclear HIF1α expression in locally advanced HNSCC patients treated with chemoradiation with or without nimotuzumab.
Patel U; Pandey M; Kannan S; Samant TA; Gera P; Mittal N; Rane S; Patil A; Noronha V; Joshi A; Patil VM; Prabhash K; Mahimkar MB
Br J Cancer; 2020 Dec; 123(12):1757-1766. PubMed ID: 32939054
[TBL] [Abstract][Full Text] [Related]
38. [Genetic variations in MLH3 and MSH2 genes are associated with the sensitivity and prognosis in locally advanced rectal cancer patients receiving preoperative chemoradiotherapy].
Yang J; Wang X; Zou SM; Li HM; Xiao Q; Feng YR; Huang Y; Feng T; Chen JN; Lin DX; Li YX; Jin J; Tan W
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):433-440. PubMed ID: 29936769
[No Abstract] [Full Text] [Related]
39. Increased expression of ERCC2 gene in head and neck cancer is associated with aggressive tumors: a systematic review and case-control study.
Zafeer M; Mahjabeen I; Kayani MA
Int J Biol Markers; 2016 Feb; 31(1):e17-25. PubMed ID: 26659720
[TBL] [Abstract][Full Text] [Related]
40. Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.
Tecza K; Pamula-Pilat J; Lanuszewska J; Grzybowska E
Oncotarget; 2016 Oct; 7(41):66790-66808. PubMed ID: 27527855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
